Back to top
more

STERIS (STE)

(Delayed Data from NYSE)

$228.43 USD

228.43
589,151

+1.56 (0.69%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $228.48 +0.05 (0.02%) 7:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's What Key Metrics Tell Us About Steris (STE) Q4 Earnings

by Zacks Equity Research

Although the revenue and EPS for Steris (STE) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Steris (STE) Surpasses Q4 Earnings Estimates

by Zacks Equity Research

Steris (STE) delivered earnings and revenue surprises of 5.79% and 0.09%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is it Worth Retaining Boston Scientific Stock in Your Portfolio Now?

by Zacks Equity Research

Investors continue to be optimistic about BSX, courtesy of its international expansion efforts and strategic acquisitions.

Zacks Equity Research

Nuwellis, Inc. (NUWE) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Nuwellis (NUWE) delivered earnings and revenue surprises of -53.33% and 23.84%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

QIAGEN Stock Gains Following the Acquisition of Genoox

by Zacks Equity Research

QGEN inks an agreement to acquire Genoox for $70 million in cash. The acquisition expands QIAGEN's QDI portfolio.

Zacks Equity Research

What Analyst Projections for Key Metrics Reveal About Steris (STE) Q4 Earnings

by Zacks Equity Research

Get a deeper insight into the potential performance of Steris (STE) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Zacks Equity Research

Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) delivered earnings and revenue surprises of 21.05% and 6.15%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Applied Sterilization Growth Help STE Beat Q4 Earnings Estimates?

by Zacks Equity Research

STERIS is expected to have experienced an increase in bioprocessing demand in the fourth quarter.

Zacks Equity Research

Hologic (HOLX) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Hologic (HOLX) delivered earnings and revenue surprises of 0.98% and 0.34%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is it the Right Time to Hold STERIS Stock in Your Portfolio?

by Zacks Equity Research

STE stays on investors' radars due to the strength of its Healthcare arm and strong rebound potential in the AST segment.

Zacks Equity Research

Intuitive Surgical (ISRG) Moves 14.3% Higher: Will This Strength Last?

by Zacks Equity Research

Intuitive Surgical (ISRG) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

Penumbra (PEN) Down 8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Penumbra (PEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Waters (WAT) Down 3.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Waters (WAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Should You Continue to Retain STERIS Stock in Your Portfolio Now?

by Zacks Equity Research

Investors continue to keep an eye on STE due to its promising Healthcare arm and AST segment's prospects.

Zacks Equity Research

Steris (STE) Up 3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Steris (STE) International Revenue in Focus: Trends and Expectations

by Zacks Equity Research

Examine the evolution of Steris' (STE) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

Zacks Equity Research

STE Q3 Earnings In Line, '25 Sales View Cut, Stock Up in Aftermarket

by Zacks Equity Research

STERIS' third-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The lowered revenue guidance for fiscal 2025 is concerning.

Zacks Equity Research

Steris (STE) Reports Q3 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Steris (STE) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Steris (STE) Matches Q3 Earnings Estimates

by Zacks Equity Research

Steris (STE) delivered earnings and revenue surprises of 0% and 0.67%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

The Zacks Analyst Blog Highlights Boston Scientific, Hologic, BioTechne, STERIS and Align

by Zacks Equity Research

Boston Scientific, Hologic, BioTechne, STERIS and Align are included in this Analyst Blog.

Zacks Equity Research

Can Steris (STE) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

Steris (STE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Urmimala Biswas headshot

Can These 5 MedTech Stocks Hit Earnings Targets This Season?

by Urmimala Biswas

Here is a sneak peek into how five MedTech stocks, BSX, HOLX, TECH, STE and ALGN, are expected to fare in their quarterly results, slated to be released tomorrow.

Zacks Equity Research

Wall Street's Insights Into Key Metrics Ahead of Steris (STE) Q3 Earnings

by Zacks Equity Research

Get a deeper insight into the potential performance of Steris (STE) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Zacks Equity Research

STE Gears Up for Q3 Earnings: Here's What You Need to Know

by Zacks Equity Research

STERIS' third-quarter fiscal 2025 results are likely to reflect the positives of normalizing the Healthcare backlog and increasing bioprocessing demand.

Zacks Equity Research

Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.